Quality of Life Research

, Volume 18, Issue 5, pp 527–530

How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses



  1. 1.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360.Google Scholar
  2. 2.
    Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMedGoogle Scholar
  3. 3.
    Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika, 75, 800–802. doi:10.1093/biomet/75.4.800.CrossRefGoogle Scholar
  4. 4.
    Sankoh, A. J., Huque, M. F., & Dubey, S. D. (1997). Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Statistics in Medicine, 16, 2529–2542. doi:10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J.PubMedCrossRefGoogle Scholar
  5. 5.
    Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000). Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet, 355, 1064–1069. doi:10.1016/S0140-6736(00)02039-0.PubMedCrossRefGoogle Scholar
  6. 6.
    Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.1016/j.jclinepi.2003.08.009.PubMedCrossRefGoogle Scholar
  7. 7.
    Horton, R. (2000). Commentary: From star signs to trial guidelines. Lancet, 355, 1033–1034. doi:10.1016/S0140-6736(00)02031-6.PubMedCrossRefGoogle Scholar
  8. 8.
    Peto, R. (1990). Misleading subgroup analyses in GISSI. The American Journal of Cardiology, 66, 771–772. doi:10.1016/0002-9149(90)91149-Z.PubMedCrossRefGoogle Scholar
  9. 9.
    Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.1001/jama.266.1.93.PubMedCrossRefGoogle Scholar
  10. 10.
    Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://www.hta.nhs.uk/fullmono/mon533.pdf. Accessed 12 March 2009.
  11. 11.
    Grouin, J.-M., Coste, M., & Lewis, J. (2005). Subgroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics, 15, 869–882. doi:10.1081/BIP-200067988.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.1056/NEJMsr077003.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Institute of Applied Health SciencesUniversity of Aberdeen Medical SchoolAberdeenUK
  2. 2.Department of Cancer Research and Molecular Medicine, Faculty of MedicineNorwegian University of Science and TechnologyTrondheimNorway
  3. 3.Quality of Life Office, Psycho-Oncology Cooperative Research Group, School of PsychologyUniversity of SydneySydneyAustralia

Personalised recommendations